Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. (Q38793287)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

Maximilian Julve

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

James Larkin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

language of work or name

English

0 references

publication date

12 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

31 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

1031-1038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

Mutations of the BRAF gene in human cancer

31 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Genomic Classification of Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1168805

10.1517/14656566.2016.1168805

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27027150%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference